【摘要】：目的:關(guān)注替加環(huán)素治療顱內(nèi)耐藥菌感染的研究進展。方法:查閱近年來國內(nèi)外相關(guān)文獻,對替加環(huán)素治療顱內(nèi)耐藥菌感染的9例病例進行歸納和分析。結(jié)果與結(jié)論:替加環(huán)素治療顱內(nèi)耐藥菌感染多用于革蘭陰性耐藥菌感染,給藥方式主要為靜脈給藥,維持劑量多為50 mg,bid,大多與其他抗菌藥物聯(lián)用。由于替加環(huán)素較大的表觀分布容積和較差的血腦屏障透過能力,導致腦脊液中的藥物濃度遠低于治療要求,從藥理學上很難解釋替加環(huán)素在合并用藥方案中的有效性。提高替加環(huán)素在腦脊液中的藥物濃度的給藥方式有待進一步研究。
[Abstract]:Objective: to investigate the progress of tigicycline in the treatment of intracranial drug-resistant bacteria infection. Methods: 9 cases of intracranial drug-resistant bacteria infection treated by tegacycline were summarized and analyzed by referring to the relevant literature at home and abroad in recent years. Results and conclusion: tigicycline was used in the treatment of intracranial drug-resistant bacteria infection, the main way of administration was intravenous administration, and the maintenance dose of 50 mg,bid, was mostly combined with other antimicrobial agents. Because of the large apparent distribution volume of tegicycline and poor blood-brain barrier permeability, the drug concentration in cerebrospinal fluid is much lower than the therapeutic requirement. It is difficult to explain the pharmacological efficacy of tegacycline in combined drug treatment. The way to increase the concentration of tegicycline in cerebrospinal fluid needs further study.
【作者單位】： 首都醫(yī)科大學附屬北京天壇醫(yī)院藥學部;首都醫(yī)科大學化學生物學與藥學院;
【基金】：國家自然科學基金資助項目(No.81301118) 多肽及小分子藥物北京市重點實驗室開放課題計劃(No.2014DTYW03) 首都醫(yī)科大學學生科研創(chuàng)新項目(No.XSKY2015181)
【分類號】：R741

【參考文獻】

相關(guān)期刊論文 前1條

1 孫桂鳳;陳，

本文編號：2305447